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Abstract
Neoadjuvant therapy is increasingly being used in the management of breast cancer patients and, since 
comprehensive specimen handling and precise histological reporting is essential to assess the degree of response to 
therapy, histopathologists are acknowledged to play a key role in this multidisciplinary setting. However, as a matter 
of fact, only minimal guidelines for specimen handling are on record. This means that in every day routine practice 
it is not uncommon for oncologists to deal with pathology reports where important parameters are missing (such 
as formal comments about therapy response). According to the latest American Joint Committee on Cancer (AJCC) 
staging classification, posttreatment size of residual disease (ypT) should be estimated based on the best combination 
of imaging, gross and microscopic histological findings. Therefore, pathologists should ideally be provided with 
clinical and radiological information before proceeding with careful grossing. During the cut-up, large sections or 
extensive mapping of samples submitted to microscopic evaluation should be carried out to reconstruct the disease 
extent: this is particularly crucial when the lesion is unapparent both at imaging and at macroscopic observation. 
Histopathological reports cannot preclude from mandatory information about the presence of residual invasive 
carcinoma, such as histotyping, staging (ypTNM), reevaluation of prognostic and predictive factors, and categorization 
of degree of response according to dedicated classification systems (performed by comparing pretreatment biopsies 
with surgical specimens). In this review we will analyze the critical issues in such an assessment and we will provide a 
pragmatic approach with the intent to aim at the “perfect” pathology report.
Background and Critical Issues
Neoadjuvant treatment (NAT) has represented a major para-
digm shift in the management of breast cancer over the last 
years and it is increasingly being used (1,2). In the context of 
clinical trials NAT has offered a unique opportunity for the 
evaluation of treatment response, with pathological complete 
response (pCR) acting as a surrogate marker of survival, thus 
1) allowing more rapid assessment of the efficacy of new chem-
otherapeutic agents, 2)  enabling early ending of ineffective 
treatments, and 3)  providing an opportunity to individualize 
patient treatment at early stages (1). In addition, it offers the 
possibility to collect tumor samples before, during, and after 
treatment facilitating translational research to identify mark-
ers of response (3).
Each expertise taking part in the multidisciplinary team 
involved in NAT for breast cancer patients has to face critical 
issues. From a pathology standpoint, handling of surgical breast 
cancer specimens has proven challenging and pathologists have 
to come up with a dedicated approach to sort out troublesome 
sampling and reporting. A crucial point of the whole concept of 
NAT is represented by the assessment of degree of response to 
therapy that has been shown to correlate with patient outcome 
(4). Indeed, pCR is associated with long-term survival and has 
been adopted as the primary endpoint for neoadjuvant trials 
(5–10).
Based on a multidisciplinary vision of the issue, it has to 
be acknowledged that assessment of disease extension (resid-
ual tumor burden) at the end of NAT is a major challenge for 
radiologists before pathologists. Indeed, evaluation of disease 
extension based on imaging guides the decision on the best 
surgical approach for single patients. With the introduction of 
magnetic resonance imaging the accuracy in discriminating 
residual disease versus pCR has improved (11). However, it may 
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occur to perform NAT on large lesions and to end up still per-
forming mastectomy due to persistence of a large lesion that, 
at histopathological observation, is reported as residual fibrosis 
only [false-positive rate reported around 6% (12)]. On the other 
hand, cases described as “complete responders” at imaging may 
have at histological observation either small foci of carcinoma, 
scattered neoplastic cells [false-negative rate reported around 
11% (12)], or neoplastic embolization [C. Marchio and A. Sapino, 
The perfect histopathology report 
PATIENT INFORMATION 
-  Patient clinical information (age, distant metastasis)  
- Radiological  information before and after NAT (size, 
morphology and location of the tumor, multifocality, 
ultrasound examination of the axylla) 
-  NAT treatment (details) 
- Accurate histopathological features assessed on biopsies 
before NAT 
GROSS DESCRIPTION
NON-pCR DIAGNOSIS pCR DIAGNOSIS
Mandatory info:
- Tumor histological type, size, multifocality
- Lymph node assessment  
- Staging (ypTNM)  
- Surgical margins 
- Prognostic & predictive factors 
Optional info:  
- Necrosis, fibrosis 
- Grading 
Categorization of tumor response to therapy according to published 
classification systems (MANDATORY INFO): 
- In the mammary gland 
- In the axillary lymph nodes 
Mandatory info:
- Description of  residual in situ lesions (if 
present) with margin evaluation 
Optional info:
- Description of changes induced by 
t r e a t m e n t ( f i b r o s i s , n e c r o s i s , 
calcifications) in the breast and in the 
axillary lymph nodes (recommended for 
radiological-histological correlations) 
Performed by 
comparing pre-NAT 
core biopsy with 
surgical specimen 
Mandatory info:
- Histotype, tumor cellularity, 
necrosis 
- Grade 
- ER/PR/HER2/Ki67 
- Sentinel lymph node 
Optional info:
- Microscopic images (to be 
compared with the 
histopathological features of 
the surgical specimen) 
Mandatory info:
- Description of macroscopic appearance and measurement of 
disease extension 
- Whenever macroscopic appearance is inconspicuous, best to 
proceed by sampling with macroblocks or multiple sampling 
with mapping 
Optional info:
- Whenever macroscopic appearance is inconspicuous, if 
available, adopt photographic documentation (by using 
instruments such as Macropath ) 
Pre-NAT biopsies Post-NAT surgical specimen 
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Figure 1. Schematic representation of a pathology report for a surgical specimen in a patient subjected to neoadjuvant treatment (NAT) before surgery. ER = estrogen 
receptor; pCR = pathologic complete response; PR = progesterone receptor. 
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personal observation and (13)]. Altogether these data bring to the 
forefront the controversial facets of residual disease assessment 
by imaging, which strongly impacts on the balance between 
overtreatment (less conservative surgical procedure) and under-
estimation of disease burden (minimal residual disease with 
pervasive lymphovascular neoplastic embolization). Williams 
et al. (12) have recently reported in their cohort a 67% of patients 
undergoing mastectomy after NAT versus 33% receiving breast 
conserving surgery.
Moving to a histopathological perspective, when focusing 
on the assessment of residual tumor burden hot topics involve 
mainly sampling methods and type of information reported. For 
these pragmatic issues a solution is here suggested, whereas for 
others, such as the clinical significance of vascular embolization 
only and of residual small foci of cancer cells, just speculative 
hypotheses can be made and questions remain to be answered.
Best Practice Recommendations: 
A Roadmap Toward the “Perfect” 
Pathology Report
Biopsy Reporting Before NAT
In our daily practice correct and standardized evaluation of the 
surgical specimens after NAT starts with an accurate evalu-
ation of all features characterizing the carcinoma before NAT. 
Therefore, in terms of pathological assessment of response it 
is crucial to correctly define, within the pretreatment setting, 
the nature of different lesions composing large tumor masses. 
In our experience, sampling of different tumor areas by multiple 
core biopsies before NAT is instrumental to define the precise 
nature of the lesion (benign vs malignant, in situ vs invasive), 
the different tumor histological types, and the heterogeneity of 
the expression of predictive markers (hormone receptors, HER2, 
and Ki67) (4). For example, it is demonstrated that infiltrating 
carcinomas of lobular histological type have a poor response to 
chemotherapy and rarely show histological changes after NAT 
compared with invasive ductal carcinomas (14). Conversely, high 
grade invasive carcinomas of triple-negative phenotype may 
show a massive response to chemotherapy, probably due to high 
proliferation indices (15). In addition, an accurate description of 
tumor cellularity and type of stroma (sclerotic vs edematous) of 
the pre-NAT biopsies are crucial to correctly assess the response 
to treatment after NAT. Microscopic images of pre-NAT biop-
sies may be of help particularly for cases managed at different 
institutions (Figure  1). Ultrasound examination of the axillary 
lymph nodes should be reported as well, to plan the sentinel 
node biopsy (4).
Gross Handling and Reporting of Surgical Specimens 
After NAT
A recent study within a national neoadjuvant breast cancer trial 
has found a considerable variability both in terms of pathology 
sampling (methods and extension), reporting and, most impor-
tantly, in the interpretation of response to treatment (1). These 
results stress the need for consensus guidelines among trial 
groups on histopathology reporting, and the participation of 
histopathologists throughout the development and analysis of 
neoadjuvant trials (1). The pathologists of the European Working 
Group For Breast Cancer Screening have actually considered the 
pathological reporting of post-NAT specimens in the supple-
ment “Quality Assurance Guidelines for Pathology Updates” that 
will soon be available. In addition, according to the latest TNM 
classification system (16), posttreatment size of residual disease 
(ypT) should be estimated based on the best combination of 
imaging, gross and microscopic histological findings. Therefore, 
it is mandatory to have radiologic information attached to the 
pathology request. Some radiologists mark the site and extent 
of the tumor before NAT by using tattoos or clips. This will be 
particularly useful for sampling of surgical specimens in cases 
of pCR. Whenever a lesion is unapparent to both imaging modal-
ities and gross pathological examination, the ways to estimate 
residual invasive cancer size are: 1) by using large section pro-
cessing (macroblocks and macrosections) (17,18) or 2) by careful 
measuring and recording the relative positions of tissue samples 
submitted to microscopic evaluation and by determining which 
contain invasive cancer (16) (Figure 1). Photographic documen-
tation of sampling is extremely helpful in this respect and for 
accurate evaluation of the status of resection margins (Figure 1). 
The examination of sentinel lymph node after NAT should be 
as accurate as possible, but molecular test (such as One Step 
Nucleic Acid Amplification assay, ie, OSNA (19)) and immunocy-
tochemistry for cytokeratins are not recommended (20).
At microscopic observation, histotyping, staging (ypTNM), 
presence of in situ carcinoma (particularly requested for the 
evaluation of margin status in breast conserving surgery), 
reevaluation of prognostic and predictive factors, and categori-
zation of degree of response according to dedicated classification 
systems are mandatory fields. Although grading is a predictive 
parameter of response to NAT and must be accurately assessed 
before treatment, chemotherapy may alter the nuclear mor-
phology and preclude a correct grading on surgical specimens. 
Optional features to be included in the report are represented 
by description of changes suggesting response to chemotherapy 
(fibrosis, necrosis) (Figure 1). Presence of calcification outside or 
within in situ lesions may be described. These alterations could 
be usefully compared with the imaging reports to improve the 
interpretation of residual disease by radiologists.
While the pCR is easily derived from the diagnosis of absence 
of residual tumor, Provenzano et al. (1) have recently highlighted 
that, in their experience, a formal comment about therapy 
response is missing in up to 55% of all non-pCR cases. This may 
be due to the plethora of classification systems described and 
proposed so far or, alternatively, to the unavailability of the pre-
treatment biopsy to compare the surgical specimens with (espe-
cially for cases managed at different institutions). As a general 
concept, it should be considered that all of the systems recog-
nize a category of pCR and a category of no response, with a vari-
able number of categories of partial response (4) [for a detailed 
description of the different available classifications, see table 1 
in (4)].
Conclusions
NAT is increasingly used in daily practice and it is, by antonoma-
sia, the best example of multidisciplinary approach for breast 
cancer patients. Multidisciplinarity is of utmost importance to 
plan the most tailored therapeutic approach and to guarantee 
an accurate evaluation of response to treatment. From a strict 
pathological standpoint, pathologists should perform a care-
ful grossing and complete microscopic description by compar-
ing also, whenever possible, the surgical specimens with the 
pretreatment biopsies. Given the large offer of classification 
systems, the type of formal comment on patient’s response 
should be wisely shared with oncologists and radiologists and 
standardized as much as possible. Standardization of minimal 
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requirements of the histopathology report is instrumental to 
provide oncologists with the right background to plan the sec-
ond phase of treatment to be addressed to these patients (adju-
vant therapy).
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